Explore
Validate
Learn
Western blot
ELISAAntibody data
- Antibody Data
- Antigen structure
- References [5]
- Comments [0]
- Validations
- Western blot [1]
- Immunohistochemistry [2]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 12166-1-AP - Provider product page
- Provider
- Proteintech Group
- Proper citation
- Proteintech Cat#12166-1-AP, RRID:AB_10640583
- Product name
- Dysadherin antibody
- Antibody type
- Polyclonal
- Description
- Dysadherin antibody (Cat. #12166-1-AP) is a rabbit polyclonal antibody that shows reactivity with human, mouse and has been validated for the following applications: IHC, WB,ELISA.
- Reactivity
- Human, Mouse
- Host
- Rabbit
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 20ul, 150ul
Submitted references miR-1180 Targets FXYD5 to Regulate Pancreatic Cancer Cells Migration and Invasion.
Generation of the novel anti-FXYD5 monoclonal antibody and its application to the diagnosis of pancreatic and lung cancer.
FXYD domain containing ion transport regulator 5 (FXYD5) silencing promotes cell viability and alleviates inflammatory response in cerulein-induced AR42J cells by blocking JAK2/STAT3 signaling pathway.
Development and Clinical Validation of a Seven-Gene Prognostic Signature Based on Multiple Machine Learning Algorithms in Kidney Cancer.
A FXYD5/TGF‑β/SMAD positive feedback loop drives epithelial‑to‑mesenchymal transition and promotes tumor growth and metastasis in ovarian cancer.
Xie H, Li J, Lu M, Zhang R, Mao H
Molecular biotechnology 2024 Nov;66(11):3182-3194
Molecular biotechnology 2024 Nov;66(11):3182-3194
Generation of the novel anti-FXYD5 monoclonal antibody and its application to the diagnosis of pancreatic and lung cancer.
Hotta T, Nariai Y, Kajitani N, Kadota K, Maruyama R, Tajima Y, Isobe T, Kamino H, Urano T
Biochimie 2023 May;208:160-169
Biochimie 2023 May;208:160-169
FXYD domain containing ion transport regulator 5 (FXYD5) silencing promotes cell viability and alleviates inflammatory response in cerulein-induced AR42J cells by blocking JAK2/STAT3 signaling pathway.
Ding L, Li J
Bioengineered 2022 Feb;13(2):2639-2647
Bioengineered 2022 Feb;13(2):2639-2647
Development and Clinical Validation of a Seven-Gene Prognostic Signature Based on Multiple Machine Learning Algorithms in Kidney Cancer.
Tian M, Wang T, Wang P
Cell transplantation 2021 Jan-Dec;30:963689720969176
Cell transplantation 2021 Jan-Dec;30:963689720969176
A FXYD5/TGF‑β/SMAD positive feedback loop drives epithelial‑to‑mesenchymal transition and promotes tumor growth and metastasis in ovarian cancer.
Bai Y, Li LD, Li J, Chen RF, Yu HL, Sun HF, Wang JY, Lu X
International journal of oncology 2020 Jan;56(1):301-314
International journal of oncology 2020 Jan;56(1):301-314
No comments: Submit comment
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- mouse small intestine tissue were subjected to SDS PAGE followed by western blot with 12166-1-AP(FXYD5 antibody) at dilution of 1:500
- Sample type
- tissue
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- Immunohistochemical of paraffin-embedded human kidney using 12166-1-AP(FXYD5 antibody) at dilution of 1:50 (under 10x lens)
- Sample type
- tissue
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- The Dysadherin antibody from Proteintech is a rabbit polyclonal antibody to a recombinant protein of human Dysadherin. This antibody recognizes human, mouse antigen. The Dysadherin antibody has been validated for the following applications: ELISA, WB, IHC analysis.
